Temozolomide-d3 (Synonyms: Methazolastone-d3, TMZ-d3) |
| Catalog No.GC48141 |
Le témozolomide-d3 (NSC 362856-d3) est le témozolomide marqué au deutérium. Le témozolomide (NSC 362856) est un agent alkylant oral actif de l'ADN qui traverse la barrière hémato-encéphalique. Le témozolomide est également un agent proautophagique et proapoptotique. Le témozolomide est efficace contre les cellules tumorales caractérisées par de faibles taux d'O6-alkylguanine ADN alkyltransférase (OGAT) et un système fonctionnel de réparation des mésappariements. Le témozolomide a des effets antitumoraux et antiangiogéniques.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 208107-14-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Temozolomide-d3 (TMZ-d3) contains three deuterium atoms located on the methyl group. It is intended for use as an internal standard for the quantification of temozolomide by GC- or LC-MS. TMZ is an imidazotetrazine that is converted to a compound capable of alkylating DNA, thus interfering with DNA replication and leading to cytotoxicity in proliferating cells.1 TMZ is rapidly and completely absorbed from the gastrointestinal tract after oral administration and readily crosses the blood-brain barrier.1 Formulations containing TMZ are effective in a variety of types of cancer, including aggressive brain cancers.1,2,3
1.Marchesi, F., Turriziani, M., Tortorelli, G., et al.Triazene compounds: Mechanism of action and related DNA repair systemsPharmacol. Res.56(4)275-287(2007) 2.Khan, O.A., Ranson, M., Michael, M., et al.A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancerBr. J. Cancer98(10)1614-1618(2008) 3.Daniel, R.A., Rozanska, A.L., Mulligan, E.A., et al.Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699Br. J. Cancer103(10)1588-1596(2010)
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *